Cardiac Complications in Immune Checkpoint Inhibition Therapy

Cardiac Complications in Immune Checkpoint Inhibition Therapy

Immune checkpoint inhibitors (ICIs) have changed the treatment landscape of advanced cancers. Unfortunately, these agents can induce a wide spectrum of immune-related adverse events (irAEs) through activation of immune responses in non-target organs, including the heart. As the clinical use of ICI t...

Full description

Bibliographic Details
Main Authors: Kazuko Tajiri, Masaki Ieda
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-01-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
immune checkpoint inhibitors
myocarditis
cardiotoxicity
programmed cell death protein 1
cytotoxic T-lymphocyte antigen 4
immune-related adverse events
Online Access:https://www.frontiersin.org/article/10.3389/fcvm.2019.00003/full

Internet

https://www.frontiersin.org/article/10.3389/fcvm.2019.00003/full

Similar Items